In this proteomics-driven cohort of advanced GC treated with first-line PD-1 inhibitor plus chemotherapy, baseline plasma proteomes were shown to stratify patients by outcome, and an immune-enriched signature provided strong prognostic discrimination. This evidence concerns the gene PDCD1 and gastric cancer.